Navigation Links
Niiki Pharma Forms Scientific Advisory Board with Leading U.S. Oncologists
Date:2/1/2012

HOBOKEN, N.J. and PHILADELPHIA, Feb. 1, 2012 /PRNewswire/ -- Niiki Pharma Inc. announced today the formation of its Scientific Advisory Board. Daniel Haller M.D. will chair the advisory board, and will be joined by Lee Ellis M.D. and Matt Kulke M.D. The Board will provide clinical and strategic guidance to the company for its two first-in-class clinical stage anti-cancer compounds, NKP-1339 and NKP-2235. As the pipeline continues to mature, the Advisory Board will be expanded.

The initial focus of the board will be Niiki Pharma's promising lead compound, NKP-1339. NKP-1339, a small molecule that down-regulates GRP78, has recently completed the dose-escalation portion of its Phase I clinical trial.

"Although we have an increasing number of drugs for a diverse spectrum of diseases, new drugs that may have higher benefit and lower toxicity for our patients are always needed," said Dr. Haller. "This Board welcomes the opportunity to participate in the development of these agents."

Dr. Daniel Haller is internationally renowned in the field of oncology. He is currently Professor of Medicine in the Department of Medicine at the Abramson Cancer Center at the University of Pennsylvania. In addition to his leadership in clinical research throughout the NCI and cancer cooperative group system, Dr. Haller is currently co-chair of the NCI Gastrointestinal Intergroup. He served as Editor-in-Chief of the Journal of Clinical Oncology, the official journal of the American Society of Clinical Oncology (ASCO), was the Associate Editor of the Annals of Internal Medicine and was Editor-in-Chief of PDQ, the National Cancer Institute's cancer information database.

Dr. Lee Ellis is an internationally recognized surgical oncologist, researcher, and leader in the field of translational oncology. He holds several positions at University of Texas MD Anderson Cancer Center, including Professor of Surgery and Cancer Biology; Director, Metastasis Re
'/>"/>

SOURCE Niiki Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
2. Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
3. Niiki Pharma Reports on Synergistic Activity of Novel Anti-Cancer Agent NKP-1339 with Other Anti-Cancer Agents
4. Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... EMERYVILLE, Calif. , Sept. 17, 2014 /PRNewswire/ ... newest data analytics solution that brings complete visibility ... minimize risks in an ever-evolving reimbursement landscape. Powered ... Integrity brings transparency to the critical point between ... operations impact revenue. The solution will improve revenue ...
(Date:9/17/2014)... MADISON, Tenn. , Sept. 17, 2014 ... be; these infections are not only uncomfortable, they,re often ... best-laid social plans. pH-D Feminine Health Support ( http://ph-defense.com ... vaginal health. It is an all-natural, homeopathic product. ... the most common symptoms of vaginal infection. In many ...
(Date:9/17/2014)... , Sept. 17, 2014  Aratana Therapeutics, Inc. ... company focused on licensing, developing and commercializing innovative ... pricing of its public offering of 4,500,000 shares of its ... of $9.25 per share. Aratana has granted the ... an additional 675,000 shares of its common stock. ...
Breaking Medicine Technology:MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3New Product from Vireo Systems: pH-D Feminine Health Support 2Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2
... DELAND, Fla., May 13 USHIFU, LLC, the clinical ... pleased,to announce conditional written approval pending minor changes to ... for the treatment of,recurrent prostate cancer with the Sonablate(R) ... Dr. Herbert Lepor, Chairman of Urology at NYU ...
... Products Expand Infection Prevention Business, DUBLIN, Ohio, ... products and services that improve the safety and,productivity ... the,acquisition of assets of privately held Enturia, Inc., ... ChloraPrep(R) brand name., ChloraPrep(R) brand products are ...
Cached Medicine Technology:FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer 2Cardinal Health Completes Enturia Acquisition 2
(Date:9/17/2014)... (PRWEB) September 17, 2014 Wright ... Conserve line of metal-on-metal hip replacements continue to ... U.S. District Court, Northern District of Georgia, Bernstein ... List issued by the U.S. Judicial Panel on ... 397 product liability claims have been filed in ...
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 Smart ... Editor’s Picks by Progressive Grocer, a leading trade magazine ... was awarded for originality and flavor, among other attributes. ... as an Editor’s Pick in the September print issue ... Grocer website. , The pizza won based on its ...
(Date:9/17/2014)... Suwanee, GA (PRWEB) September 17, 2014 ... proud to announce the launch of its new vegan ... mask is extremely effective and provided the results skincare ... was to create a gentle yet active mask that ... CEO Lake Louise.” , This Sugar Cane Fruit Mask ...
(Date:9/17/2014)... -- Present-day Europeans are the descendants of at ... a new study. Previous research suggested ... European farmers. But, a new genetic analysis involving ... descendants of Ancient North Eurasians. Nearly all present-day ... group, researchers from Harvard Medical School said. , ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, ... who turn to artificial sweeteners to soothe their sweet ... new Israeli study suggests. Artificial sweeteners can potentially ... researchers found in human and mouse studies. That,s ... bacteria residing in the intestines in ways that can ...
Breaking Medicine News(10 mins):Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 2Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 3
... in what triggers jealousy in men and women, study finds ... in the eye of the beholder, a new study suggests. ... to men while emotional infidelity may be of greater concern ... experiences in previous relationships may be even more important. , ...
... notes bloating, stomach pain, fatigue also point to less ... Relying on symptoms alone to identify women who have ... early, a new study indicates. , Research shows that ... healthy women to report symptoms such as abdominal pain, ...
... Jan. 28 Baylor Sammons Breast Center at ... has been recognized by the National Accreditation Program for Breast ... every significant advantage in their battle against breast disease." The ... NAPBC. Accreditation by the NAPBC is only given to those ...
... , ST. PAUL, Minn. , Jan. 28 ... -based Campbell Mithun, has been named Event Chair for this year’s ... Minnesota’s only nonprofit organization to supply life-saving blood and blood components ... to have Jeff Naughtin on board to head this ...
... , TORRANCE, Calif. , Jan. 28 ... is often a renewed focus on personal health and nutrition. ... year are prebiotics and immune health. This is welcome news ... addresses both categories. , SPINS, the leading provider of ...
... past or future, study finds , THURSDAY, Jan. 28 (HealthDay ... look toward the future, their body language reflects their sense ... the University of Aberdeen fitted subjects with motion sensors and ... past. The bodies of those who thought about the future ...
Cached Medicine News:Health News:Personal History Linked to Feelings of Betrayal 2Health News:Symptoms Alone Don't Spot Ovarian Cancer Early 2Health News:Symptoms Alone Don't Spot Ovarian Cancer Early 3Health News:Breast Center at Baylor Dallas Recognized for Commitment to Fighting Breast Disease 2Health News:Breast Center at Baylor Dallas Recognized for Commitment to Fighting Breast Disease 3Health News:Memorial Blood Centers Names Campbell Mithun’s Jeff Naughtin Event Chair for What’s Your Type? Benefit 2Health News:Memorial Blood Centers Names Campbell Mithun’s Jeff Naughtin Event Chair for What’s Your Type? Benefit 3Health News:Sun Chlorella USA Positioned for Strong 2010 2
... Digital Wide Field Lens combines ... high magnification. The enhanced double ... provide high resolution stereo views ... reflections. These unique features make ...
... Stereo Fundus Lens is specifically designed for ... retina. Its enhanced 3-D stereoscopic design enables ... detail, making it ideal for detecting changes ... serous detachments and other macular abnormalities. It ...
The Pan Retinal® 2.2 uniquely combines magnification nearly that of the 20D lens with a field of view approaching that of the 30D lens. Excellent for virtually every examination procedure, includ...
... Volks state-of-the-art 20D diagnostic/laser lens ... astigmatic aberrations and coma delivering ... 20 diopter lens on the market. ... maintains linear image magnification and perfect ...
Medicine Products: